Recent SGMO News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/30/2024 09:23:28 PM
- Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec • Business Wire • 12/30/2024 09:15:00 PM
- Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases • PR Newswire (US) • 12/19/2024 07:30:00 AM
- Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases • Business Wire • 12/19/2024 07:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 09:09:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 09:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 09:08:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 09:07:25 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/20/2024 05:15:14 AM
- Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain • Business Wire • 11/19/2024 09:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/12/2024 10:25:20 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/12/2024 10:24:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:02:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 09:01:18 PM
- Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results • Business Wire • 11/12/2024 09:01:00 PM
- Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast • Business Wire • 11/04/2024 09:15:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/28/2024 08:11:50 PM
- Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 • Business Wire • 10/22/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:03:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:38:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:38:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:37:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:37:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 08:36:34 PM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM
UAV Corp (OTC: UMAV) Engages Legal Counsel to Initiate Uplisting Process with Ultimate Goal of NASDAQ Listing • UMAV • Jan 15, 2025 8:30 AM
HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer • HLYK • Jan 15, 2025 8:00 AM
Zefiro Methane Corp. Subsidiary Awarded Slate of Government of Ohio-Funded Environmental Remediation Projects • ZEFI • Jan 15, 2025 7:33 AM